Drs. Hornstein, Brown, and Grewal examine a groundbreaking phase 3 trial press release for a pan-RAS inhibitor in second-line metastatic pancreatic cancer, showing a striking doubling of overall survival compared with standard chemotherapy. They explain how targeting the active KRAS state represents a major shift from prior mutation-specific approaches, potentially benefiting up to 90% of patients. The group also highlights practical implications including rapid expected uptake, the importance of comprehensive molecular testing, and manageable toxicity with proactive care. Overall, this marks a potential paradigm shift in pancreatic cancer treatment, with ongoing trials poised to move these agents into earlier lines of therapy.
